These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38615906)

  • 1. Implementation of new treatments for BCG-unresponsive non-muscle-invasive bladder cancer. Considerations in Latin America.
    Fernández MI
    Actas Urol Esp (Engl Ed); 2024 May; 48(4):257-259. PubMed ID: 38615906
    [No Abstract]   [Full Text] [Related]  

  • 2. Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
    Tan WS; Grajales V; Bree K; Li R; Nogueras-Gonzalez GM; Navai N; Dinney C; Kamat AM
    BJU Int; 2023 Oct; 132(4):384-386. PubMed ID: 37246493
    [No Abstract]   [Full Text] [Related]  

  • 3. SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.
    Kulkarni GS; Wettstein MS
    Eur Urol; 2023 Dec; 84(6):545-546. PubMed ID: 37802681
    [No Abstract]   [Full Text] [Related]  

  • 4. OncoTherad
    Alonso JCC; de Souza BR; Reis IB; de Arruda Camargo GC; de Oliveira G; de Barros Frazão Salmazo MI; Gonçalves JM; de Castro Roston JR; Caria PHF; da Silva Santos A; de Freitas LLL; Billis A; Durán N; Fávaro WJ
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
    Duquesne I; de la Taille A
    Eur Urol; 2024 Jul; 86(1):74-75. PubMed ID: 38538425
    [No Abstract]   [Full Text] [Related]  

  • 6. ADAPT and Improvise: Overcoming Bacillus Calmette-Guérin Unresponsiveness in Non-muscle-invasive Bladder Cancer.
    Maitre P; Sangar V; Choudhury A
    Eur Urol; 2023 Jun; 83(6):495-496. PubMed ID: 36898871
    [No Abstract]   [Full Text] [Related]  

  • 7. Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
    Kikuchi E; Ng CF; Kitamura H; Ku JH; Lee LS; Lin TP; Ng JYS; Nishiyama H; Poon DM; Kanesvaran R; Seo HK; Spiteri C; Tan EM; Tsai YS; Tran B
    Int J Urol; 2024 Jan; 31(1):32-38. PubMed ID: 37795933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Goto Y
    Int J Urol; 2023 Nov; 30(11):957-958. PubMed ID: 37608457
    [No Abstract]   [Full Text] [Related]  

  • 9. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
    Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
    Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer.
    Kim SK; Byun YJ; Park SH; Piao XM; Zheng CM; Moon S; Kim K; Song SJ; Kang HW; Kim WT; Lee OJ; Choi YH; Moon SK; Kim WJ; Choi YD; Kim SY; Yun SJ
    Eur Urol; 2024 Apr; 85(4):400-402. PubMed ID: 38216401
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer.
    Smaldone MC; Gingrich JR
    Minerva Urol Nefrol; 2010 Jun; 62(2):129-32. PubMed ID: 20562792
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ⅱ. Clinical Evidence and Biological Mechanism of BCG Failure in Patients with Non-Muscle Invasive Bladder Cancer].
    Miyake M
    Gan To Kagaku Ryoho; 2022 Jan; 49(1):33-38. PubMed ID: 35046358
    [No Abstract]   [Full Text] [Related]  

  • 13. Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
    Moussa M; Abou Chakra M; Shore ND; Papatsoris A; Farahat Y; O'Donnell MA
    Arch Ital Urol Androl; 2024 Mar; 96(1):12244. PubMed ID: 38502039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer.
    Ferro M; Barone B; Crocetto F; Lucarelli G; Busetto GM; Del Giudice F; Maggi M; Crocerossa F; Cantiello F; Damiano R; Borghesi M; Bove PL; Papalia R; Mari A; Luzzago S; Soria F; Marchioni M; La Civita E; Terracciano D; Mistretta FA; Piccinelli M; Marmiroli A; Russo GI; Schips L; Hurle R; Contieri R; Perdonà S; Del Prete P; Mirone V; Tataru OS; Musi G; Montanari E; de Cobelli O; Vartolomei MD
    Urol Oncol; 2022 Nov; 40(11):490.e13-490.e20. PubMed ID: 35676172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
    Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Okajima E; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
    World J Urol; 2024 Mar; 42(1):185. PubMed ID: 38512511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
    Nykopp TK; Batista da Costa J; Mannas M; Black PC
    Curr Urol Rep; 2018 Oct; 19(12):101. PubMed ID: 30357541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III.
    Reike MJ; Ingersoll MA; Müller DC; Zuiverloon TCM; Strandgaard T; Kamat AM; Williams SB; Seiler R; Todenhöfer T; Dyrskjøt L; Nawroth R; Goebell P; Schmitz-Dräger B; Sfakianos JP; Meeks J; Horowitz A; Black PC
    Urol Oncol; 2023 May; 41(5):211-218. PubMed ID: 36266219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure.
    Pignot G; Baboudjian M; Lebacle C; Chamouni A; Lechevallier E; Irani J; Tillou X; Waeckel T; Monges A; Doisy L; Walz J; Gravis G; Mourey E; Duperron C; Masson-Lecomte A
    World J Urol; 2023 Nov; 41(11):3195-3203. PubMed ID: 36811732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guerin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC- 1901-BCG.
    Ram P; Mandal S; Das MK; Nayak P
    Urology; 2023 Mar; 173():229. PubMed ID: 36587796
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
    Bedke J; Black PC; Szabados B; Guerrero-Ramos F; Shariat SF; Xylinas E; Brinkmann J; Blake-Haskins JA; Cesari R; Redorta JP
    Urol Oncol; 2023 Dec; 41(12):461-475. PubMed ID: 37968169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.